Participants were randomly assigned to receive retatrutide (4 mg, 9 mg, or 12 mg) or placebo by once-weekly subcutaneous injection (134, 133, 136, and 134 individuals, respectively).The researchers found that for the treatment regimen estimand, the mean change from baseline in hemoglobin A1c concentration was 1.69, 1.86, and 1.94 percent with 4, 9, and 12 mg of retatrutide, respectively, versus 0.81 percent with placebo, resulting in estimated treatment differences of 0.88, 1.04, and 1.12 percent, respectively, versus placebo
These symptoms warrant medical review
EBioMedicine 66, 103293
Iyengar, N
[DOI] [PMC free article] [PubMed] [Google Scholar] 157.Dobrowolny G., Giacinti C., Pelosi L., Nicoletti C., Winn N., Barberi L., Molinaro M., Rosenthal N., Musaro A